Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.79 |
| ▸ | EGFR | P00533 | 6/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.76 |
| ▸ | AURKA | O14965 | 2/20 | 0.76 |
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.67 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473619 | 0.92 | MAPK14 (0.81) | MAPK14EGFRAURKBAURKAKDR | |
| Anilinoquinazoline1 SCHEMBL1066538 | 0.87 | AURKB (1.00) | MAPK14EGFRAURKBAURKAKDR | |
| Anilinoquinazoline1 SCHEMBL30195580 | 0.87 | AURKB (1.00) | MAPK14EGFRAURKBAURKAKDR | |
| SCHEMBL21473615 | 0.87 | KDR (0.72) | MAPK14EGFRAURKBKDRIRAK4 | |
| SCHEMBL6794349 | 0.86 | MAPK14 (0.81) | MAPK14EGFRAURKBAURKAKDR | |
| Anilinoquinazoline1 SCHEMBL3968007 | 0.86 | AURKB (0.98) | MAPK14EGFRAURKBAURKAKDR | |
| SCHEMBL6785711 | 0.85 | MAPK14 (1.00) | MAPK14EGFRAURKBAURKAKDR | |
| Hydrochloric Acid SCHEMBL6782357 | 0.84 | MAPK14 (0.98) | MAPK14EGFRAURKBAURKAKDR | |
| SCHEMBL8933899 | 0.84 | AURKB (0.94) | MAPK14EGFRAURKBAURKAKDR | |
| Hydrochloric Acid SCHEMBL8807597 | 0.83 | AURKB (0.92) | MAPK14EGFRAURKBAURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3778586-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | East China University of Science and Technology (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019196938-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EGFR, ERBB2, ERBB4 | MAPK14 323/4885EGFR 1/4885AURKB 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.